These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16736003)

  • 1. An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma.
    Royston P; Reitz M; Atzpodien J
    Br J Cancer; 2006 Jun; 94(12):1785-8. PubMed ID: 16736003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractional polynomials in a new metastatic renal carcinoma continuous prognostic index involving histology, laboratory, and clinical predictors.
    Atzpodien J; Royston P; Stoerkel S; Reitz M
    Cancer Biother Radiopharm; 2007 Dec; 22(6):812-8. PubMed ID: 18158772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
    Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building multivariable regression models with continuous covariates in clinical epidemiology--with an emphasis on fractional polynomials.
    Royston P; Sauerbrei W
    Methods Inf Med; 2005; 44(4):561-71. PubMed ID: 16342923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
    Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
    Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
    Manola J; Royston P; Elson P; McCormack JB; Mazumdar M; Négrier S; Escudier B; Eisen T; Dutcher J; Atkins M; Heng DY; Choueiri TK; Motzer R; Bukowski R;
    Clin Cancer Res; 2011 Aug; 17(16):5443-50. PubMed ID: 21828239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
    Patil S; Ishill N; Deluca J; Motzer RJ
    Cancer; 2010 Jan; 116(2):347-54. PubMed ID: 19921736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
    Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
    Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.